The antibiotic resistance crisis: Part 2: Management strategies and new agents

P and T

Volumn 40, Issue 5, 2015, Pages 344-352

  Lee Ventola, C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM PLUS CEFTAZIDIME; CEFTAROLINE; CEFTOLOZANE; DALBAVANCIN; DORIPENEM; ORITAVANCIN; TEDIZOLID; TELAVANCIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GOVERNMENT REGULATION; HEALTH CARE CONCEPTS; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH PERSONNEL ATTITUDE; HEALTH PROGRAM; HUMAN; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84929081985     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (25)

1. Golkar Z, Bagazra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. Infect Dev Ctries 2014;8(2):129–136.
2. Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can overcome microbial resistance. Virulence 2013;4(2):185–191.
3. Wright GD. Something new: revisiting natural products in antibiotic drug discovery. Can J Microbiol 2014;60(3):147–154.
4. Sengupta S, Chattopadhyay MK, Grossart HP. The multifaceted roles of antibiotics and antibiotic resistance in nature. Front Microbiol 2013;4:47.
5. Centers for Disease Control and Prevention, Office of Infectious Disease. Antibiotic resistance threats in the United States, 2013. April 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013. Accessed February 20, 2015.
6. Congressional Research Service Report. Life expectancy in the United States. March 2005. Available at: http://www.cnie.org/ nle/crsreports/05mar/RL32792.pdf. Accessed January 5, 2015.
7. Lushniak BD. Antibiotic resistance: a public health crisis. Public Health Rep 2014;129(4):314–316.
8. Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013;56(10):1445–1450.
9. Michael CA, Dominey-Howes D, Labbate M. The antibiotic resistance crisis: causes, consequences, and management. Front Public Health 2014;2:145.
10. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Clin Opin Pharmacol 2014;18C;58–60.
11. Luyt CE, Brechot N, Trouillet JL, Chastre J. Antibiotic stewardship in the intensive care unit. Crit Care 2014;18(5):480.
12. Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis 2014;59 suppl 2:S71–S75.
13. The antibiotic alarm. Nature 2013;495(7440):141.
14. Piddock LJ. The crisis of no new antibiotics— what is the way forward? Lancet Infect Dis 2012;12(3):249–253.
15. Gelles D. Merck in $8.4 billion deal for Cubist, big maker of antibiotics. The New York Times. December 8, 2014. Available at: http://dealbook.nytimes.com/2014/12/08/merck-agreesto- acquire-drug-maker-cubist-for-9-5-billion. Accessed January 5, 2015.
16. The Pew Charitable Trust. GAIN: How a new law is stimulating the development of antibiotics. November 7, 2013. Available at: http://www.pewtrusts.org/en/research-and-analysis/ issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-thedevelopment- of-antibiotics. Accessed January 5, 2015.
17. Tavernise S, Shear M. Obama seeks to double funding to fight antibiotic resistance. The New York Times. March 27, 2015. Available at: http://www.nytimes.com/2015/03/28/us/politics/obamaseeks- to-double-funding-to-fight-antibiotic-resistance.html?_r=0. Accessed April 4, 2015.
18. Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes 2014;5(1):3–4.
19. Gross M. Antibiotics in crisis. Curr Biol 2013;23(24):R1063–R1065.
20. Centerwatch. FDA approved drugs for infections and infectious disease. Available at: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/25/infections-andinfectious-diseases. Accessed February 27, 2015.
21. Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbial Antimicrob 2013;12:22.
22. The Pew Charitable Trust. Antibiotics currently in clinical development. December 31,2014. Available at: http://www.pewtrusts.org/en/multimedia/data-visualizations/2014/antibiotics- currently-inclinical- development. Accessed February 28, 2015.
23. Zerbaxa (ceftozolane/tazobactam) prescribing information. December 2014. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2014/206829lbl.pdf. Accessed February 28, 2015.
24. Mendes C, Antunes A. Pipeline of known chemical classes of antibiotics. Antibiotics 2013;2(4):500–534.
25. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistances. Nature 2015;517:455–459.